JRC Publications Repository

JRC Publications Repository >

Browsing by Author MORGENSTERN Alfred

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:   
Sort by: In order: Results/Page Authors/Record:
Showing results 12 to 31 of 136
Publication YearTitleAuthor(s), Editor(s), Other Contributor(s)Publication Type
2013Alpha-particle emitting 213Bi-anti-EGFR immunoconjugates eradicate tumor cells independent of oxygenationWULBRAND Christian; SEIDL C.; GAERTNER F. C.; BRUCHERTSEIFER Frank; MORGENSTERN Alfred; ESSLER M.; SENEKOWITSCH-SCHMIDTKE R.Articles in Journals
2013Alpha-Particle Immunotherapy for Acute Myeloid Leukemia (AML) with Bismuth-213 (213Bi) and Actinium-225 (225Ac)JURCIC J. G.; ROSENBLAT Todd; MCDEVITT Michael; PANDIT-TASKAR N.; CARRASQUILLO Jorge; SGOUROS G.; MORGENSTERN Alfred; CICIC Dragan; LARSON S. M.; SCHEINBERG D. A.Contributions to Conferences
2010[An(H2O)9](CF3SO3)3 (An=U-Cm, Cf): Exploring Their Stability, Structural Chemistry, and Magnetic Behavior by Experiment and TheoryAPOSTOLIDIS Christos; SCHIMMELPFENNIG Bernd; MAGNANI Nicola; LINDQVIST-REIS Patric; WALTER Olaf; SYKORA Richard; MORGENSTERN Alfred; COLINEAU Eric; CACIUFFO Roberto; KLENZE R., et alArticles in Journals
2009Analysis of DNA double-strand breaks in gastric cancer cells after treatment with 213Bi-immunoconjugatesSEIDL C.; FRANK Annette; PFOST B.; MORGENSTERN Alfred; BRUCHERTSEIFER Frank; SENEKOWITSCH-SCHMIDTKE ReingardContributions to Conferences
2011Analysis of Patient Survival in a Phase 1 Trial of Systemic Targeted Alpha Therapy for Metastatic MelanomaALLEN B. J.; SINGLA A; RAJA C.; RIZVI S.; GRAHAM P.; BRUCHERTSEIFER Frank; APOSTOLIDIS Christos; MORGENSTERN AlfredArticles in Journals
2013Anti-PSMA labeled liposomes loaded with Actinium-225 for potential alpha-particle radiotherapy of tumor vasculatureBANDEKAR Amey; ZHU Charles; JINDAL Rohit; BANERJEE Sangeeta Ray; POMPER Martin; BRUCHERTSEIFER Frank; MORGENSTERN Alfred; SOFOU StavroulaContributions to Conferences
2014Anti-PSMA labeled liposomes loaded with Actinium-225 for potential antivascular alpha-radiotherapyZHU Charles; BANDEKAR Amey; BANERJEE Sangeeta Ray; POMPER Martin; BRUCHERTSEIFER Frank; MORGENSTERN Alfred; SOFOU StavroulaContributions to Conferences
2014Anti-tumour immunity induced after alpha irradiationGORIN J; MENAGER J; GOUARD S.; MAUREL C; GUILLOUX Yannick; FAIVRE-CHAUVET A; MORGENSTERN Alfred; BRUCHERTSEIFER Frank; CHEREL M.; DAVODEAU F, et alArticles in Journals
2006Antibody-guided Alpha Radiation Effectively Damages Fungal BiofilmsMARTINEZ L.r.; BRYAN R.a.; APOSTOLIDIS CHRISTOS; MORGENSTERN ALFRED; CASADEVALL A.; DADACHOVA E.Articles in Journals
2014Anti–Prostate-Specific Membrane Antigen Liposomes Loaded with 225Ac for Potential Targeted Antivascular a-Particle Therapy of CancerBANDEKAR Amey; ZHU Charles; JINDAL Rohit; BRUCHERTSEIFER Frank; MORGENSTERN Alfred; SOFOU StavroulaArticles in Journals
2012Bismuth-213 and Actinium-225 – Generator Performance and Evolving Therapeutic Applications of Two Generator-Derived Alpha-Emitting RadioisotopesMORGENSTERN Alfred; BRUCHERTSEIFER Frank; APOSTOLIDIS ChristosArticles in Journals
2008Bismuth-213 Radioimmunotherapy with C595 Anti¿MUC1 Monoclonal Antibody in an Ovarian Cancer Ascites ModelSONG E.; QU C. F.; RIZVI S.; RAJA C.; BERETOV J.; MORGENSTERN Alfred; APOSTOLIDIS Christos; BRUCHERTSEIFER Frank; PERKINS A. D.Articles in Journals
2014Branched Amphiphilic Peptide Capsules: Cellular Uptake and Retention of Encapsulated SolutesSUKTHANKAR Pinakin; AVILA Adriana; WHITAKER Susan; IWAMOTO Takeo; MORGENSTERN Alfred; APOSTOLIDIS Christos; LIU Ke; HANZLIK Robert; DADACHOVA E.; TOMICH JohnArticles in Journals
2007Breaking Chemo- and Radioresistance with [Bi-213]anti-CD45 Antibodies in Leukemia CellsFRIESEN C.; GLATTING G.; KOOP B.; SCHWARZ K.; MORGENSTERN ALFRED; APOSTOLIDIS CHRISTOS; DEBATIN K.m.; RESKE S.n.Articles in Journals
2012Clinical aspects and future advances of targeted alpha therapy in oncologyKRATOCHWIL Clemens; GIESEL Frederik; MORGENSTERN AlfredContributions to Conferences
2012Combined 213Bi-DTPA- F3 and paclitaxel treatment of peritoneal spread of human ovarian carcinoma in a mouse model enhances therapeutic efficacy due to enhanced induction of apoptosis and G2/M phase cell-cycle arrestSEIDL C.; VALLON M.; BLECHERT B.; GILBERTZ K.-P.; AICHLER M; FEUCHTINGER A; GÄRTNER Florian; BRUCHERTSEIFER Frank; MORGENSTERN Alfred; ESSLER M.Contributions to Conferences
2013Comparative analysis of alpha radioimmunotherapy with bismuth-213-labeled anti-CD138 antibody and Melphalan chemotherapy for the treatment of multiple myeloma.GOUARD S.; PALLARDY A; GASCHET J; FAIVRE-CHAUVET A; BRUCHERTSEIFER Frank; MORGENSTERN Alfred; MAUREL C; KRAEBER BODÉRÉ F; BARBET J; DAVODEAU F, et alContributions to Conferences
2014Comparative analysis of multiple myeloma treatment by CD138 antigen targeting with bismuth-213 and Melphalan chemotherapy.GOUARD S.; PALLARDY A; GASCHET J; FAIVRE-CHAUVET A; BRUCHERTSEIFER Frank; MORGENSTERN Alfred; MAUREL C; MATOUS E; KRAEBER BODÉRÉ F; DAVODEAU F, et alArticles in Journals
2014Comparison of the alpha-decay half-life of 210Po implanted in a copper matrix at 4.2 and 293 KPOEML PHILIPP; BELLONI F.; D'AGATA Elio; COLINEAU Eric; MORGENSTERN Alfred; GRIVEAU Jean-Christophe; RONDINELLA Vincenzo; REPNOW R; NASSISI V.; BENNEKER P, et alArticles in Journals
2012Comparison of therapeutic efficacy and biodistribution of 213Bi- and 211At-labeled monoclonal antibody MX35 in an ovarian cancer modelGUSTAFSSON Anna; BAECK Tom; ELGQVIST Joergen; JACOBSSON Lars; HULTBORN Ragnar; ALBERTSSON Per; MORGENSTERN Alfred; BRUCHERTSEIFER Frank; JENSEN Holger; LINDEGREN StureArticles in Journals
Showing results 12 to 31 of 136

 

The mission of the JRC is to provide customer-driven scientific and technical support for the conception, development, implementation and monitoring of EU policies. As a service of the European Commission, the JRC functions as a reference centre of science and technology for the Union. Close to the policy-making process, it serves the common interest of the Member States, while being independent of special interests, whether private or national.
Powered by DSpace
Top